Researchers are shifting how they treat pancreatic ductal adenocarcinoma (PDAC), focusing on the KRAS mutation that drives more than 90% of cases. This mutation locks KRAS in an “on” state, causing continuous cancer cell growth and making the disease resistant to many standard treatments, including immunotherapy.
New findings show KRAS also shapes the tumor’s immune environment. It promotes signals that recruit immune-suppressing cells and block T cells, keeping tumors “cold” and difficult for the immune system to detect. This process begins early in disease development, limiting natural anti-tumor responses.
After years of being considered untargetable, KRAS is now the focus of new drug strategies, including mutation-specific inhibitors, broader RAS blockers, and protein degraders. Early research suggests combining these drugs with immunotherapy may improve outcomes by reactivating immune responses.
While promising, challenges remain. Potential toxicity, limited effectiveness in low–T cell tumors, and uncertain translation from animal models to humans continue to be key hurdles.